1. Home
  2. GOSS vs JYNT Comparison

GOSS vs JYNT Comparison

Compare GOSS & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$0.34

Market Cap

101.2M

Sector

Health Care

ML Signal

HOLD

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.92

Market Cap

120.7M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
JYNT
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Multi-Sector Companies
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
101.2M
120.7M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
GOSS
JYNT
Price
$0.34
$8.92
Analyst Decision
Buy
Strong Buy
Analyst Count
8
2
Target Price
$4.19
$17.00
AVG Volume (30 Days)
10.5M
52.5K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
133.93
EPS
N/A
0.19
Revenue
$48,471,000.00
$117,696,356.00
Revenue This Year
N/A
$12.23
Revenue Next Year
$144.43
N/A
P/E Ratio
N/A
$46.89
Revenue Growth
N/A
15.49
52 Week Low
$0.32
$7.50
52 Week High
$3.87
$13.47

Technical Indicators

Market Signals
Indicator
GOSS
JYNT
Relative Strength Index (RSI) 28.06 57.13
Support Level $0.33 $8.01
Resistance Level $0.60 $9.05
Average True Range (ATR) 0.04 0.29
MACD 0.05 0.09
Stochastic Oscillator 13.87 81.68

Price Performance

Historical Comparison
GOSS
JYNT

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: